Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT04108897 · ClinicalTrials.gov registry record · Early Phase 1

Analysis of the Microbiome in Rosacea

A Early Phase 1 study of Rosacea, sponsored by Johns Hopkins University.

Active
Registry status
Early Phase 1
Development phase
150
Enrollment target
1
Study location

NCT04108897: Active Early Phase 1 study of Rosacea, sponsored by Johns Hopkins University.

NCT04108897 is a Early Phase 1 study of Rosacea that is active but no longer recruiting, run by Johns Hopkins University. The registered enrollment target is 150 participants, below the 237-participant average among 23 other Rosacea trials with a reported enrollment target (37% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT04108897, a Early Phase 1 study of Rosacea, is active but no longer recruiting, sponsored by Johns Hopkins University.

ACTIVE NOT RECRUITING
Registry status
Early Phase 1
Development phase
150 participants
Enrollment target
1
Study location

Study Summary

The skin and gut microbiome of rosacea patients differs from individuals without rosacea and that the microbiome suffers from unique derangements in rosacea patients following antibiotic therapy. This study was proposed to examine microbial signatures of the skin and gut microbiome in patients with moderate to severe rosacea and to identify differences between microbe communities in patients with rosacea and volunteers without rosacea using 16S ribosomal ribonucleic acid (rRNA) polymerase chain reaction (PCR) amplification, sequencing and computational phylogenetics and to assess alterations in the gut and skin microbiota of patients with moderate to severe rosacea in response to varying formulations of antimicrobial treatment.

Primary Outcome

Differences between microbe communities in patients with rosacea and controls without rosacea will be assessed using a 16S rRNA PCR amplification, sequencing and computational phylogenetics.

Conditions Studied

Interventions

  • DRUG Doxycycline
  • DRUG Ivermectin Topical

Study Locations (1)

Maryland

  • Cutaneous Translational Research Program, Department of Dermatology - Baltimore

Trial Details

FieldValue
Enrollment Target 150 participants
Start Date 2019-09-17
Est. Completion 2027-09
Phase Early Phase 1
Johns Hopkins University

1,448 total trials

What the registry record for NCT04108897 still lists

NCT04108897 is an interventional study that assigns participants to a tested intervention. The registered 150 participants enrollment target is mid-sized for trials with a published cap, below the 237-participant average among 23 other Rosacea trials with a reported enrollment target (37% lower).

The record links to 1 condition, with Rosacea appearing as the primary indexed condition, and to 2 interventions - of which Doxycycline is the first listed.

NCT04108897 reports a single indexed study location in Maryland.

Frequently Asked Questions

What is clinical trial NCT04108897 about?

NCT04108897 is a clinical study titled "Analysis of the Microbiome in Rosacea". The skin and gut microbiome of rosacea patients differs from individuals without rosacea and that the microbiome suffers from unique derangements in rosacea patients following antibiotic therapy. This study was proposed to examine microbial signatures of the skin and gut microbiome in patients with...

What is the current status of trial NCT04108897?

This trial is currently active not recruiting. It is a Early Phase 1 study. The enrollment target is 150 participants. The study started on 2019-09-17. Estimated completion is 2027-09.

What conditions does trial NCT04108897 study?

This clinical trial studies the following conditions: Rosacea.

What interventions are being tested in trial NCT04108897?

The interventions under investigation include: Doxycycline (DRUG), Ivermectin Topical (DRUG).

Who is sponsoring clinical trial NCT04108897?

This trial is sponsored by Johns Hopkins University, which has 1,448 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT04108897 being conducted?

This trial has 1 study location across Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Rosacea

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT04108897's enrollment target sits among peer trials

150 10th of 23 higher than 13 of 23 other Rosacea trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Rosacea trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT00412594 · 150 participants · Phase 2

    Cladribine and Rituximab in Treating Patients With Hairy Cell Leukemia

  • NCT01484730 · 150 participants

    A Pilot Study to Evaluate Multi-Spectral and Laser Speckle Imaging and Multiphoton Microscopy During Vascular Occlusion

  • NCT01985919 · 150 participants

    Protocol for Facilitating the Acquisition of Research Bone Marrow and Blood Samples

  • NCT02016248 · 150 participants · NA

    SBRT Boost for Unfavorable Prostate Cancer'

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT04108897, the US trial registry maintained by the National Library of Medicine. NCT04108897 (mid enrollment · single site footprint · active not recruiting) retrieved and formatted by PlainTrial, see methodology.